Asia Pacific Protein A Resins Market Share was valued at USD 116.3 million in 2019 and is expected to witness 9.0% CAGR from 2019 to 2026.
Get more details on this report - Request Free Sample PDF
Improving scenario pertaining to drug discovery and development in the emerging economies of the region will positively impact Asia Pacific protein A resins market growth in the forthcoming years. Several biopharmaceutical firms are operational in the region that are investing largely into drug discovery. Use of protein A resins has become the gold standard for drug discovery and is often used during drug approval process. Thus, with advancing drug therapy and approval, the demand for protein A resins will expand in the future years.
With growing incidence of cancer, autoimmune diseases, and numerous orphan diseases, the adoption of monoclonal antibodies (mAbs) will grow rapidly in the forthcoming years. Antibody drugs are gaining traction for treatment of such diseases. Protein A resins deliver successful purification of mAbs, thus driving its adoption rate. Despite of the advantages and wide application, high cost may impede the market growth to a certain extent.
Asia Pacific Share Market, By Application
Based on application, the market is segmented as immunoprecipitation (IP) and antibody purification. Demand for protein A resins for immunoprecipitation will foresee significant increase at over 9.0% CAGR during the forecast timeframe. IP is used for affinity purification of antigens at small scale. It allows scientists to enrich for low-abundance proteins to fortify downstream analysis. Protein A resin based agarose matrix is used widely or immunoprecipitation due to favourable outcome, that will in turn drive the segmental growth.
Asia Pacific Size Market, By Product
Based on product, protein A resins market comprises natural protein A resins and recombinant protein A resins. Natural protein A segment held more than USD 35 million in 2019. The first protein A resin was natural protein A, Sepharose Fast Flow (FF). It provided multipoint attachment of the protein A ligand to the base matrix. However limited benefits of natural protein A resins may restrict its segmental growth.
Asia Pacific Value, By Matrix Type
Based on matrix type, the market is segmented as agarose-based matrix, glass or silica gel-based matrix and organic polymer-based matrix. Organic polymer-based matrix segment held considerable revenue share in 2019. This type of matrix offers high strength stiffness and several advantages compared to other matrixes. Thus, owing to benefits of organic polymers as matrix for protein A resins, its demand will gradually increase over the upcoming years.
Asia Pacific Forecast, By End-use
Based on end-use, the market is segmented as biopharmaceutical companies, clinical research laboratories, academic research institutes, and contract research organizations. Clinical research laboratories end-use segment will foresee about 9.5% CAGR during the analysis period. Increasing spending on drug development and clinical trials will influence adoption of protein A resins in the region. Furthermore, rising research activities associated with immunotherapy will spur the segmental growth in the coming years.
Asia Pacific Trends, By Country
China protein A resins market accounted for around USD 23 million segment size in 2019 and will proceed at rapid pace in the foreseeable future. Growing focus on advancement and expansion of applications of monoclonal antibodies in the country will augment China protein A resins market growth. Growing emphasis on research and development and expanding number of pharmaceutical and biotechnology firms will impel the business size over the estimation period.
Competitive Market Share
The major industry players involved in market involve GE Healthcare, EMD Millipore, Thermo Fisher Scientific, Repligen and Bio-Rad Laboratories among others. Players are adopting business expansion strategies such as partnerships and product launch. For instance, in May 2016, JHL Biotech (JHL) opened biopharmaceutical manufacturing facility with single-use bioprocessing technology in China. The company will use KUBio manufacturing solution delivered by GE Healthcare to produce monoclonal antibodies (mAbs) and biosimilars for commercial supply and late–stage clinical trials.
Protein A resins were initially developed forty years back. Orthoclone was the first therapeutic antibody using Protein A chromatography for its purification over 30 years ago. Protein A was then utilized for capturing mAbs in regulatory submissions. Several improvements have been made in protein A resins market since its commercialization and have now become the gold standard for mAb purification. Remarkable performance and high capabilities are the chief factors attributable to high demand. With continuously expanding biotechnology firms in the region, the demand for protein A resins will grow rapidly in the foreseeable future.